Hoth Therapeutics (HOTH) has been granted a patent for the HT-KIT platform by the Japan Patent Office on May 7, with exclusive protection until August 27, 2039. The granted patent protects Hoth’s approach of using splice-switching oligonucleotides to selectively disrupt KIT gene expression in mast cells-cells implicated in conditions ranging from chronic hives to rare cancers. HT-KIT is one of several novel platforms under development at Hoth Therapeutics.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics announces Expanded Access Program aplication for HT-001
- Hoth Therapeutics Prepares Presentation on Clinical Programs
- Hoth Therapeutics Faces Nasdaq Compliance Challenge
- Hoth Therapeutics reports preclinical data for HT-KIT
- Hoth Therapeutics granted Japanese patent for novel RNA-based cancer therapy
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue